Shenzhen RuiJin Pharmaceutical Co.,Ltd

      China anabolic steroid hormone raw powders professional supplier

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsPolypeptide Hormones

White Injectable GHRH Human Growth Hormone Powder CJC-1295 With DAC 2mg/Vial

I'm Online Chat Now
Certification
China Shenzhen RuiJin Pharmaceutical Co.,Ltd certification
China Shenzhen RuiJin Pharmaceutical Co.,Ltd certification
I really enjoy doing business with your company, the self confidence and courage i am able to help my clients with the product i make from yourpowder.

—— Frank

You have a good service and a good product.The safe shipping makes my business get better , so crazy. thank you. ill buy more in next order .

—— Kris

Hi Gavin,You service is outstanding.Even here in USA you would be ranked very highly.Realy like your product and service.Will try more in next circle

—— Carlos

I was hugely impressed with your efficiency and product quality. gavin ,u product makes me lots money .

—— Dave

White Injectable GHRH Human Growth Hormone Powder CJC-1295 With DAC 2mg/Vial

White Injectable GHRH Human Growth Hormone Powder CJC-1295 With DAC 2mg/Vial
White Injectable GHRH Human Growth Hormone Powder CJC-1295 With DAC 2mg/Vial White Injectable GHRH Human Growth Hormone Powder CJC-1295 With DAC 2mg/Vial

Large Image :  White Injectable GHRH Human Growth Hormone Powder CJC-1295 With DAC 2mg/Vial Get Best Price

Product Details:
Place of Origin: China
Brand Name: CJC-1295 With DAC
Certification: SGS,ISO9001,HKAS,GMP
Model Number: 51753-57-2
Payment & Shipping Terms:
Minimum Order Quantity: 10vial
Price: Negotiable
Packaging Details: In disguised,as your requirements.
Delivery Time: within 24hours after you pay the order
Payment Terms: T/T, Western Union, MoneyGram,Bitcoin
Supply Ability: 5000Grams per month
Detailed Product Description
Appearance:: White Powder Delivery:: By DHL, TNT, FedEx, HKEMS, UPS, Etc.
Molecular Formula:: C165H271N47O46 Molecular Weight:: 3649.30
Grade:: Pharmaceutical Grade Policy: Re-sent Policy
Market: Global CAS:: 863288-34-0
High Light:

polypeptides

,

polypeptide supplements

White Injectable GHRH Human Growth Hormone Powder CJC-1295 With DAC 2mg/Vial

 
Quick Detail:

 

Product Name CJC-1295 DAC
Specification 2mg/vial
Category Peptide
Shipping Methods EMS, HKEMS, DHL, FedEx, TNT, UPS, Etc.
Delivery Time Ship immediately After Receiving Your Payment
MOQ 1 kit/ 10 vials
Payment Terms Western Union, T/T, MoneyGram, Bitcoin
Packaging Details Foil bags, Bubble papers and Paper boxes

 
 
Description:
 
1.CJC-1295 is a derivative of human GH-releasing factor1-29(HGRF1-29). HGRF1-29 is a naturally occurring peptide that is actually a truncated form of a larger peptide that binds to the growth hormone secretagogue receptor (GHS-R) and causes the release of growth hormone. CJC-1295 has four amino acids substituted in its chain that result in strong binding to serum albumin and prolong its half-life in the body.
 
2. Because of the way CJC 1295 is engineered its half life has been extended from ~7 minutes to greater than 7 days!. This is convenient as it means the product only needs to be injected 1-2 times per week for continuously elevated levels of Human Growth Hormone (HGH) and IGF-1. A single subcutaneous (sc) injection results in measurable quantities of CJC-1295 in the blood for up to 13 days. Additionally, a single dose of 60 ug/kg of CJC-1295 results in elevated levels of growth hormone (125%) while the pulsatile secretion of GH is maintained. Furthermore, 60 ug/kg of CJC 1295 elevated IGF1 levels to the upper limit of normal. A dose of 30 ug/kg of CJC-1295 given weekly maintained its response with no evidence of desensitization.
 
The advantage of using CJC 1295 instead of actual HGH injections is that injecting HGH shuts down the body's own natural production and therefore when injections are ceased, the body’s ability to produce it's own HGH may be impaired and take some time to recover. Since CJC 1295 only stimulates the body's own HGH production, this risk is not apparent. Another very positive benefit of CJC-1295/CJC-1293 is its ability to promote slow wave sleep. Slow wave sleep is also known as deep sleep and is the portion of sleep responsible for the highest level of muscle growth and memory retention. SWS are decreased significantly in older adults and also with people who tend to exercise later in the evening. This peptide has a benefit to side effect ratio that exceeds all others currently being legally sold and would make a great addition to ones training regimen or post cycle therapy. Clinical Research was first conducted for CJC-1295 during the mid 2000s. The objective of the peptide was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous hgH are presumed to increase lipolysis (fat loss). The clinical research was ultimately successful for most research subjects.
 
3. Possible benefits: Fat loss, muscle gain, increased collagen and reduced wrinkles, increased bone density, strengthened immune system, increased energy.
 
4. Dosage:
0.5mg (500mcg) taken 1-2 times per week
Doses per vial: 4 x 0.5mg doses (2 weeks worth)
When: Before bed on an empty stomach.
How: Subcutaneous injection into fat. It can be simultaneously injected in the same syringe as other peptides.
Water to mix: Add 1ml (100 units) of sterile solution to the vial. Every 500mcg is then equal to 0.25ml (25 units).
Best combined with: GHRP-6
 


What is CJC-1295 DAC Used for:

 

1. Those looking for anti-aging benefits, improved physique and sense of well being.
Administration of single doses of CJC-1295 resulted in a 2- to 10-fold increase in mean serum GH levels in all dosing groups, which was dose incremental and persisted for up to 6 days. Similarly, a dose-related increase in mean serum IGF-I levels was observed at all dose levels, ranging from 1.5- to 3-fold and persisting for up to 14 days. Administration of ascending multiple doses of CJC-1295 resulted in elevated levels of GH, similar to those observed after a single dose.
 
2. In contrast, elevations in IGF-I levels showed a progressive effect over time, particularly in subjects receiving CJC-1295 every 7 d. Results of the multiple-dose study suggest both a cumulative pharmacokinetic effect [i.e. persistence of elevated predose levels of IGF-I in all dosing groups except group 1 (i.e. two injections of 30 µg/kg)] and a pituitary priming effect (i.e.progressively greater Cmax and progressively shorter Tmax after serial dosing). The data indicate that a minimum dosing interval of 7 d appears reasonable. The most appropriate dosing interval will be determined based on actual efficacy and safety data from longer-term therapeutic studies in patients with various clinical conditions.
 
3. No serious adverse reactions were reported in either study. The most frequently reported adverse events in subjects receivingCJC-1295 were injection site reactions, consisting of transient pain, swelling, and induration that were sometimes accompanied by local urticaria. Injection site reactions tended to be more severe and/or prolonged at higher dose levels. Headache, diarrhea, and flushing were also observed, with occasional transient and mild hypotension, but occurred primarily at higher doses.
 
4. Adverse effects complicate the use of GH in the treatment of HIV-associated metabolic conditions such as wasting and lipodystrophy. Although increases in the daily dose of GH from 1 to 6 mg are associated with dose-responsive benefits, doses of 2–3 mg/d or greater are associated with edema, arthralgias, and glucose intolerance. These side effects can become dose limiting. In the current studies, none of the subjects experienced these adverse effects. Future clinical trials on this disorder will confirm whether the use of GHRH rather than GH will circumvent these problems, as has been suggested in recent publications.
 
5. In summary, a single sc administration of CJC-1295 produced sustained elevations of serum GH and IGF-I levels in normal subjects for nearly 2 wk. Weekly or biweekly administration of CJC-1295 resulted in stimulation of GH and IGF-I secretion for at least 7 d. Both single and multiple doses of CJC-1295 over 2 wk were safe and generally well tolerated, particularly at doses of 30 and 60 µg/kg. Future studies are indicated to evaluate the clinical utility of treatment with CJC-1295 in patients with intact GH secretory capacity.
 
6. Now for any GH releaser’s benefits to reach full potential, somatostatin has to be controlled because it will inhibit gh release. Using an agent known as an Acetylcholinesterase inhibitor will allow acetyl chlorine levels to rise by preventing acethylcholineesterase from overriding acetylcholine; acetylcholine will inhibit somastostatin production. An example of a natural acetylcholinieestarase would be Huzperine A. A recommended dosage for HuzperineA would be around 50mcg. Now as mentioned before a more potent pharm grade somastostatin inhibitor would be Ipamorelin.
 
7. Logically speaking it would make PERFECT sense to combine CJC-1295 with Ipamorelin since you get the increase in GH from CJC and the increase of GH pulse frequencies with a reduction in somatostatin from the Ipamorelin. This leads to a maximal GH release effect, thus allowing for maximum anabolism from optimized GH without desensitization.
 
COA:

 

Product name CJC-1295 DAC
CAS register number 863288-34-0
Molecular formula C165H271N47O46
Molecular weight 3649.30
Assay 99%
Appearance White powder
Single Impurity(HPLC) 1.0%max
Amino Acid Composition 10% of theoretical
Peptide Content(N%) 80%(by %N)
Water Content(Karl Fischer) 6.0%
Acetate Content(HPIC) 15.0%
MS (ESI) Consistent
Mass Balance 95.0~105.0%
Price Negotiated

 
 
HPLC:
White Injectable GHRH Human Growth Hormone Powder CJC-1295 With DAC 2mg/Vial 0

Contact Details
Shenzhen RuiJin Pharmaceutical Co.,Ltd

Contact Person: Gavin Lee

Tel: +8618806592208

Send your inquiry directly to us